Statutory Profit Doesnt Reflect How Good ADMA Biologics Earnings Are
ADMA Stock | USD 20.11 1.72 7.88% |
About 55% of ADMA Biologics' investor base is interested to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are impartial. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
r Sm59 BKQ6 HX cLy,,RiD-YkfVSKe I2ZUeO8glala0I5QLNKgLmcICxxDaDNg raiIPiR
Read at finance.yahoo.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
ADMA Biologics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
FATE | Fate Therapeutics | 18.28 | ||||
IBIO | Ibio | 11.79 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
TFFP | Tff Pharmaceuticals | 9.68 | ||||
SANA | Sana Biotechnology | 9.02 | ||||
MCRB | Seres Therapeutics | 6.52 | ||||
INMB | INmune Bio | 3.27 | ||||
PLRX | Pliant Therapeutics | 2.00 | ||||
PLX | Protalix Biotherapeutics | 1.78 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
AKBA | Akebia Ther | 0.49 | ||||
BCRX | BioCryst Pharmaceuticals | 0.13 | ||||
CDTX | Cidara Therapeutics | 0.05 | ||||
CRBU | Caribou Biosciences | 0.45 | ||||
ATRA | Atara Biotherapeutics | 0.65 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
ACLX | Arcellx | 1.12 | ||||
VXRT | Vaxart | 1.64 | ||||
ETNB | 89bio | 1.64 | ||||
RCUS | Arcus Biosciences | 2.28 | ||||
TNXP | Tonix Pharmaceuticals | 5.00 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |